Dynavax to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference
Dynavax Technologies (Nasdaq: DVAX) has announced that CEO Ryan Spencer will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Dynavax Technologies (Nasdaq: DVAX) has announced that CEO Ryan Spencer will present at the H.C. Wainwright Virtual BioConnect 2022 Conference scheduled for January 10-13, 2022. The on-demand presentation will be accessible starting January 10, 2022, at 7:00 a.m. E.T. on the company’s website under the 'Events & Presentations' section. Dynavax is a biopharmaceutical firm specializing in developing vaccines, including HEPLISAV-B®, which is approved for preventing hepatitis B infections in adults.
Details
News Market Reaction – DVAX
The recorded move for DVAX in the trading session of this news was +3.97%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., Jan. 5, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer, Chief Executive Officer, will present at the H.C. Wainwright Virtual BioConnect 2022 Conference being held January 10-13, 2022.
The on demand presentation will be available, beginning Monday, January 10, 2022 at 7:00 a.m. E.T. and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at http://investors.dynavax.com/events-presentations.
About Dynavax
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines to help protect the world against infectious diseases. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and the European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 adjuvant as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, plague, Tdap, seasonal influenza and universal influenza. For more information, visit www.dynavax.com and follow the company on LinkedIn.
Contacts:
Nicole Arndt
narndt@dynavax.com
510-665-7264
Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-present-at-the-hc-wainwright-virtual-bioconnect-2022-conference-301454785.html
SOURCE Dynavax Technologies
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.